In a study published December 4, 2010, researchers found that treating multiple myeloma patients early with a type of bisphosphonate called zoledronic acid improved survival. It also bolstered bone health and the risk of fracture and bone pain, common to the disease.
Of the 1,960 multiple myeloma participants, about half were treated with zoledronic acid in combination with either intensive or non-intensive chemotherapy. Even though chemotherapy intensity did not appear to affect fatality or survival outcomes, those taking zoledronic acid in proper dosages had notably higher survival rates.
No comments:
Post a Comment